Percentage expression of neutrophil activation marker in the peripheral blood of patients with dry eye disease plus type 2 diabetes
Zhmud T. M. 1, Velychko L. N. 2, Drozhzhyna G. I. 2, Bogdanova O. V. 2
1 National Pirogov Memorial Medical University, Vinnytsya; Vinnytsya (Ukraine)
2 SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
Zhmud T. M., Velychko L. N., Drozhzhyna G. I., Bogdanova O. V. Percentage expression of neutrophil activation marker in the peripheral blood of patients with dry eye disease plus type 2 diabetes. J.ophthalmol.(Ukraine).2022;1:24-9. http://doi.org/10.31288/oftalmolzh202212429
Background: Dry eye disease (DED) is a disorder of the anterior segment of the eye which is common in patients with type 2 diabetes mellitus (T2DM). It has been reported that symptoms of DED were observed in 60-70% of patients with T2DM. Given that inflammation has a key role in the progression of both T2DM and DED, we believe it is reasonable to study the role of neutrophils in this process.
Purpose: To assess the percentage expression of CD15, a neutrophil activation marker, in the peripheral blood of patients with both DED and T2DM.
Material and Methods: Forty-six patients (92 eyes; mean age, 54.0 ± 8.0 years) with both DED and T2DM were included in this study. There were 19 (40%) women and 27 (60 %) men. Mean diabetes duration was 8.0 ± 6.6 years. All patients had well-compensated diabetes. In addition to a routine examination of the eye, Schirmer I test and tear film break-up time (TBUT) test, they had their corneal fluorescein staining (CFS) scored using the Oxford schema, severities of dry eye graded according to the DEWS II classification and Ocular Surface Disease Index (OSDI) obtained. An immunohistocytochemical study was employed to assess the expression of CD15, a neutrophil activation marker, in peripheral blood cells of patients.
Results: The mean percentage expression of CD15, a neutrophil activation marker, in the peripheral blood, was 46.7% for 14 patients with T2DM plus DED and punctuate keratopathy, and 28.5% for 32 patients with T2DM plus DED and intact cornea (р=0.0001). There was a mild negative correlation between the expression of CD15 and the Schirmer score (r = -0.32; р = 0.032), and between the former and the TBUT score (r = -0.34; р = 0.019).
Keywords: type 2 diabetes mellitus, dry eye disease, neutrophil activation marker
1.Zhao H, He Y, Ren Y-R, Chen B-H. Corneal alteration and pathogenesis in diabetes mellitus. Int J Ophthalmol. 2019 Dec 18;12(12):1939-50.
2.Threatt J, Williamson JF, Huynh K, Davis RM, Hermayer K. Ocular disease, knowledge and technology applications in patients with diabetes. Am J Med Sci. 2013 Apr;345(4):266-70.
3.Zhmud ТМ, Malachkova NV, Andrushkova OO, Hrizhymalska КY. Meibomian gland dysfunction and dry eye disease symptoms in patients with type 2 diabetes mellitus. Reports of Morphology. 2019;25(4): 51-5.
4.Cowburn A S, Condiffe AM, Farahi N, et al. Advances in neutrophil biology: Clinical implications. Chest. 2008 Sep;134(3):606-612.
5.Markoulli M, Flanagan J, Tummanapalli SS, Wu J, Willcox M. The impact of diabetes on corneal nerve morphology and ocular surface integrity. Ocul Surf. 2018 Jan;16(1):45-57.
6.Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276-283.
7.Arafat SN, Suelves AM, Spurr-Michaud S, et al. Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with Stevens-Johnson Syndrome and Ocular Cicatricial Pemphigoid. Ophthalmology. 2014 Jan;121(1):79-87.
8.Arafat SN, Robert M-C, Abud T, et al. Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients. Am J Ophthalmol. – 2017 Apr;176:46-52..
9.Tibrewal S, Sarkar J, Jassim SH, et al. Tear fluid extracellular DNA: diagnostic and therapeutic implications in dry eye disease. Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8051-6.
10.Sonawane S, Khanolkar V, Namavari A, Chaudhary S, Gandhi S, Tibrewal S, et al. Ocular surface extracellular DNA and nuclease activity imbalance: A new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci. 2012;53(13):8253–63.
11.Postnikoff CK, Huisingh C, McGwin G, Nichols KK. Leukocyte distribution in the open eye tears of normal and dry eye subjects. Curr Eye Res. 2018 Oct;43(10):1253-1259.
12.Kuryltsiv NB, Zborovska OV, Velychko LM, Bogdanova OV. [Role of CD markers in the development of uveal inflammation]. Zdobutky klinichnoi i eksperymentalnoi medytsyny. 20121;2:96-101. Ukrainian.
14.Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S et al. The definition and classification of dry eye disease: report of the definition and classification. Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5 (2):75–92.
15.Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion;2003. Russian.
16.Potapnev MP, Hushchyna LM, Moroz LА. [Human neutrophils subpopulations and functions heterogeneity in norm and pathology]. Immunologiia. 2019; 40 (5): 84–96. Russian.
17.Galkin AA, Demidova VS. [Neutrophils and systemic inflammatory response syndrome]. Rany i ranevyie infektsii. Zhurnal imeni prof. B.M. Kostiuchenka. 2015;2:25-32. Russian.
18.Wedmore CV, Williams TJ. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646-50.
19.Segel G, Halterman M, Lichtman M. The paradox of the neutrophil’s role in tissue injury. J Leukoc Biol. 2011 Mar;89(3):359-72.
20.Panes J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol. 1999 Feb;126(3):537-50.
21.Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol. 2012 Jan;130(1):90-100.
22.Perez VL, Pflugfelder SC, Zhang S, Shojaei A. Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016 Apr;14(2):207-15.
23.Zhmud TM. [Intensity of redox processes in the cornea in experimental keratitis in the presence of diabetes]. Oftalmologiia. 2015;2(2):202-10. Russian.
24.Zhmud TM, Leus NF, Drozhzhyna GI. [Changes in the activity of oxidative enzymes in the cornea and tear in keratitis in the presence of diabetes]. Oftalmologiia. Vostochnaia Ievropa. 2018;8(2):221-32. Russian.
25.Drozhzhyna GI, Zhmud TM. [Experimental prerequisites for improving glutathione level in the ocular mucosa and tear in acute conjunctivitis under conditions of hyperglycemia]. Oftalmol Zh. 2014;6:66-71. Russian.
26.Zhmud TM. [Investigating redox potentials of the thiol system of the cornea in experimental keratitis in the presence of diabetes]. Oftalmol Zh. 2015;6:46-9. Ukrainian.
27.Zhmud TM. [State of the thiol system of the cornea in animal models of acute conjunctivitis and streptozotocin-induced diabetes]. Oftalmologiia. Vostochnaia Ievropa. 2015;4(27):42-8. Russian.
Acknowledgement: The authors thank O.I. Dragomiretska for her assistance in statistic analysis.
Conflict of Interest Statement: The authors declare that there is no actual or potential conflict of interest (financial, personal, professional and other interests) that could affect the opinion on the subject or materials described and discussed in this manuscript.